CN108420879A - It is a kind of to treat dermopathic drug - Google Patents
It is a kind of to treat dermopathic drug Download PDFInfo
- Publication number
- CN108420879A CN108420879A CN201710076605.2A CN201710076605A CN108420879A CN 108420879 A CN108420879 A CN 108420879A CN 201710076605 A CN201710076605 A CN 201710076605A CN 108420879 A CN108420879 A CN 108420879A
- Authority
- CN
- China
- Prior art keywords
- drug
- dermopathic
- treatment
- willow
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to traditional Chinese medicine and drug field more particularly to a kind for the treatment of dermopathic drug.Drug of the present invention is external preparation, preferably paste, ointment and film made of wild the root of straight ladybell, frutus cnidii, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material.Confirmed through pharmacodynamics test and clinical test, drug of the present invention has a good therapeutic effect to all kinds of skin diseases such as psoriasis, and drug treating both manifestation and root cause of disease of the present invention, control difficulty in relapse after healing, be widely applicable, safe to use and treatment cost it is very low.
Description
Technical field
The present invention relates to traditional Chinese medicine and drug field more particularly to a kind for the treatment of dermopathic drug.
Background technology
Psoriasis, i.e. psoriasis vulgaris are a kind of Chronic immunes mediated with multiple-factor inheritance background, T cell
Abnormality inflammatory dermatoses.The cause of disease of this disease is not yet clear so far, generally believes and heredity, infection, dysbolism, immune work(
The factors such as energy disorder, mental status, wound are related.This disease is difficult to cure completely, and easy recurrent is its main feature, usually can be anti-
Recurrence is made, and life long treatment is needed.At present clinically be used for treat this disease drug mainly have immunosuppressor, glucocorticoid,
Antibiotic, immunomodulator, retinoid and biological agent, however, said medicine still has many defects, example in use
Such as, adverse reaction is more and more serious, including bone marrow suppression, hepatic and renal function damage and blood fat raising etc., is also easy to produce drug resistance
And dependence, withdrawal reaction is will produce, easy recurrence can not be effected a radical cure, medical expense is very high.
Tinea of feet and hands, also known as tinea pedis are foot dermatosis caused by being infected by pathogenic fungus, have infectiousness.This disease
Breaking-out is also infected, endocrine, the influence of autoimmunity, mood, many factors such as diet, easily recur, the common spy of clinic
It is treated than antifungals such as naphthalene sweet smell, Itraconazole, Fluconazoles, adverse reaction is more, and hepatic disfunction person avoids use.
Impetigo, also known as infective pustule are a kind of common, superficial skin infection diseases for being communicated by contact
Disease, characterized by blister, warts, easy ulceration knot purulence scab occurs.This disease is usually caused by staphylococcus aureus, once in a while by haemolysis
Property streptococcus causes, and bacterial adhesion after skin microtrauma invades and causes to infect.The common sensitive antibiotics of clinic are to this disease
It is treated, the disadvantage is that drug resistance is easy tod produce, and also some patients will appear allergic reaction.
Cutaneous pruritus is a kind of dermatological conditions for only having itch and being damaged without primary cutaneous.The disease of cutaneous pruritus
Because mostly with environmental factor (including biological or chemical material incentive in humidity, season, working environment), external used medicine, with alkalinity
The sebaceous glands of strong soap and patient skin causes dry skin etc. related with sweat gland secretion hypofunction.The generation of pruitus
Mainly by chemical mediator as caused by the release of histamine, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, kassinin kinin and protease etc..The clinical treatment of cutaneous pruritus
Drug includes mainly local anesthetic, antihistaminic, glucocorticoid, immunosuppressor, vitamin C, Thalidomide, thio sulphur
Sour sodium and 5-hydroxytryptamine receptor antagonist etc., major defect are to be difficult to effect a radical cure easily recurrence and adverse reaction is serious.
It in summary it can be seen, be directed to above-mentioned all kinds for the treatment of for skin disease drugs at present in use all with prodigious
Limitation.Mainly cut including uncertain therapeutic efficacy, it is difficult to radical cure easily recurrence, and a variety of serious adverse reactions can be brought, it is also easy to produce resistance to
Pharmacological property and dependence have withdrawal reaction, and the compliance and tolerance of patient is poor, and administration time is long, expensive, treatment cost
With high.In consideration of it, be badly in need of in clinical practice a kind for the treatment of both manifestation and root cause of disease, uneasy to recur, widely applicable, prescription is simple, it is curative for effect,
The novel drugs that property easy to use, safe is good and treatment cost is low.The present invention is long on the basis of family and personal medical practice
Phase, which is explored, repeated authentication obtains a kind of having the advantages that the dermopathic novel drugs of above-mentioned treatment.Through experiment, drug pair of the present invention
Above-mentioned all kinds of dermopathic main clinic symptoms have ideal therapeutic effect, and control difficulty in relapse after healing, in addition, medicine of the present invention
All raw materials of object are all from natural drug, and use is very safe and reliable, are suitable for all types of dermatosis patients, therefore, the present invention
Drug is very suitable for current clinical demand.
Invention content
The technical issues of solution
Problem to be solved of the present invention is：Because being used at present for all kinds for the treatment of for skin disease drugs such as psoriasis
All there is significant limitation in journey.Such as uncertain therapeutic efficacy is cut, it is difficult to radical cure easily recurrence, and can bring a variety of serious bad anti-
It answers, is also easy to produce drug resistance and dependence, there is withdrawal reaction, the compliance and tolerance of patient is poor, and administration time is long, price
Costliness, medical expense height etc..Therefore, the above problem existing for existing medicine so that many patients cannot be timely and effectively
Treatment.
Technical solution
The present invention is intended to provide it is a kind of treat all kinds of dermopathic treating both manifestation and root cause of disease such as psoriasis, it is uneasy to recur, widely applicable,
Simple, curative for effect, the easy to use, safe property of prescription is good and the lower novel drugs for the treatment of cost.
The present invention treats dermopathic drug, it is characterised in that it is made of the raw material of following weight parts：
Wild the root of straight ladybell 13-17；Frutus cnidii 13-17；Willow bark 13-17；
Sand ground willow buddings 28-32；Nepal knotweed herb grass 15-20；
The drug is made by following steps：
Wild the root of straight ladybell, frutus cnidii, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material are mixed, water rinsing, drying, crushed
Afterwards plus 8-12 times is measured water, after impregnating 2 hours, is decocted 1-3 hours, and liquid filtration, filtrate is spare, under the same conditions by dregs of a decoction weight
It decocts 1-3 times again, continues to decoct until becoming sticky pasty masses up to this drug extract after merging filtrate.
The parts by weight of above-mentioned raw materials are preferred：
Wild the root of straight ladybell 13；Frutus cnidii 13；Willow bark 13；
Sand ground willow buddings 28；Nepal knotweed herb grass 15.
The parts by weight of above-mentioned raw materials are further preferably：
Wild the root of straight ladybell 15；Frutus cnidii 15；Willow bark 15；
Sand ground willow buddings 30；Nepal knotweed herb grass 18.
The parts by weight of above-mentioned raw materials are further preferably：
Wild the root of straight ladybell 17；Frutus cnidii 17；Willow bark 17；
Sand ground willow buddings 32；Nepal knotweed herb grass 20.
Preferably, the drug extract made from above-mentioned steps by this field it is conventional prepare paste, ointment or film
This drug paste, ointment or film is further made in method.
Moreover, it relates to a kind of application for treating dermopathic drug in preparing treatment psoriasis drug.
Further, dermopathic drug answering in preparing treatment tinea of feet and hands drug is treated the invention further relates to a kind of
With.
Further, dermopathic drug answering in preparing treatment impetigo drug is treated the invention further relates to a kind of
With.
Further, dermopathic drug is treated in preparing treatment pruitus disease drug the invention further relates to a kind of
Using.
Advantageous effect
For the present invention on the basis of family and personal medical practice, long felt, repeated authentication, which obtain, a kind for the treatment of skin
The novel drugs of skin disease.Through experiment, drug of the present invention dermopathic main clinic symptoms all kinds of to psoriasis etc., which have, preferably to be controlled
Treatment acts on, and treating both manifestation and root cause of disease of the present invention, control difficulty in relapse after healing, be widely applicable, prescription is simple, curative for effect, safety is good and
Treatment cost is very low；In addition, all raw materials of drug of the present invention are all from natural drug, use is very safe and reliable, is suitable for each
Type-skin patient, therefore, drug of the present invention are very suitable for current clinical demand, and popularization and application of the invention will have
Good market prospects simultaneously generate considerable economy and social benefit.
Specific implementation mode
Illustrate that embodiments of the present invention, those skilled in the art can be by this specification below by way of specific specific example
Disclosed content understands other advantages and effect of the present invention easily.The present invention can also pass through in addition different specific realities
The mode of applying is embodied or practiced, the various details in this specification can also be based on different viewpoints with application, without departing from
Various modifications or alterations are carried out under the spirit of the present invention.
Before further describing the specific embodiments of the present invention, it should be appreciated that protection scope of the present invention is not limited to down
State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific specific in order to describe
Embodiment, the protection domain being not intended to be limiting of the invention；In description of the invention and claims, unless in text
In addition explicitly point out, singulative "one", " one " and " this " include plural form.
When embodiment provides numberical range, it should be appreciated that except non-present invention is otherwise noted, two ends of each numberical range
Any one numerical value can be selected between point and two endpoints.Unless otherwise defined, in the present invention all technologies for using and
Scientific terminology is identical as the normally understood meaning of those skilled in the art of the present technique.Except used in embodiment specific method, equipment,
Outside material, the record according to those skilled in the art to the grasp of the prior art and the present invention can also use and this
Any method, equipment and the material of the similar or equivalent prior art of method, equipment described in inventive embodiments, material come real
The existing present invention.
The pharmacodynamic study and clinical effectiveness of drug of the present invention are carried out below in conjunction with specific embodiment and comparative example detailed
Explanation.
Embodiment 1
A kind of to treat dermopathic drug, this drug is made of the raw material of following weight parts：
Wild the root of straight ladybell 15；Frutus cnidii 15；Willow bark 15；
Sand ground willow buddings 30；Nepal knotweed herb grass 18；
Preparation method is as follows：
Wild the root of straight ladybell, frutus cnidii, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material are mixed, water rinsing, drying, crushed
Afterwards plus 10 times are measured water, after impregnating 2 hours, are decocted 2 hours, and liquid filtration, filtrate is spare, are under the same conditions repeated the dregs of a decoction pan-fried
It boils 2 times, continues to decoct until becoming sticky pasty masses up to this drug extract after merging filtrate.
Comparative example 1
A kind of to treat dermopathic drug, this drug is made of the raw material of following weight parts：
Frutus cnidii 15；Willow bark 15；
Sand ground willow buddings 30；Nepal knotweed herb grass 18；
Preparation method is as follows：
Frutus cnidii, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material are mixed, water rinses, adds 10 times after dry, crushing
Water is measured, after impregnating 2 hours, is decocted 2 hours, liquid filtration, filtrate is spare, repeats to decoct 2 times by the dregs of a decoction under the same conditions, close
And continue to decoct until becoming sticky pasty masses up to this drug extract after filtrate.
Comparative example 2
A kind of to treat dermopathic drug, this drug is made of the raw material of following weight parts：
Wild the root of straight ladybell 15；Willow bark 15；
Sand ground willow buddings 30；Nepal knotweed herb grass 18；
Preparation method is as follows：
Wild the root of straight ladybell, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material are mixed, water rinses, adds 10 times after dry, crushing
Water is measured, after impregnating 2 hours, is decocted 2 hours, liquid filtration, filtrate is spare, repeats to decoct 2 times by the dregs of a decoction under the same conditions, close
And continue to decoct until becoming sticky pasty masses up to this drug extract after filtrate.
Comparative example 3
A kind of to treat dermopathic drug, this drug is made of the raw material of following weight parts：
Wild the root of straight ladybell 15；Frutus cnidii 15；
Willow bark 15；Nepal knotweed herb grass 18；
Preparation method is as follows：
Wild the root of straight ladybell, frutus cnidii, willow bark and nepal knotweed herb herbal medicine material are mixed, water rinses, adds 10 times of amounts after dry, crushing
Water after impregnating 2 hours, decocts 2 hours, and liquid filtration, filtrate is spare, repeats to decoct 2 times by the dregs of a decoction under the same conditions, merge
Continue to decoct until becoming sticky pasty masses up to this drug extract after filtrate.
Comparative example 4
A kind of to treat dermopathic drug, this drug is made of the raw material of following weight parts：
Wild the root of straight ladybell 15；Frutus cnidii 15；
Willow bark 15；Sand ground willow buddings 30；
Preparation method is as follows：
Wild the root of straight ladybell, frutus cnidii, willow bark and sand ground willow buddings medicinal material are mixed, water rinses, adds 10 times of amounts after dry, crushing
Water after impregnating 2 hours, decocts 2 hours, and liquid filtration, filtrate is spare, repeats to decoct 2 times by the dregs of a decoction under the same conditions, merge
Continue to decoct until becoming sticky pasty masses up to this drug extract after filtrate.
Pharmacodynamics test
Pharmacodynamics test is carried out to drug obtained in above-described embodiment and comparative example.
One, test material
This experiment agents useful for same is as follows：
Test medicine：Drug made from embodiment 1, comparative example 1-4.
Experimental animal：KM mouse, weight 20-25g.
Two, modeling method
Psoriasis model：Diethylstilbestrol is injected intraperitoneally in female mice, and every 0.2mg, one time a day, continuous 3d makes at mouse
Tail skin scale number is carried out to mouse and is measured within the 6th day after the estrogen phase, the 1st injection diethylstilbestrol, compared with blank group,
If there is the scale number showed increased of stratum granulosum in model group mouse tail scale, the psoriasis model modeling success is prompted.
Cutaneous pruritus model：To 0.025% dextran 0.05ml/10g weight (1.25mg/ of mouse tail vein injection
Kg), observe its itching number and itching duration, with blank group compare, if model group mouse itching number showed increased and
Itching duration extension prompts the cutaneous pruritus model modeling success.
Three, test method
Experiment grouping：
60 mouse similar in selective body weight from modeling successful mouse, are randomly divided into 6 groups, i.e., test medicine group is (i.e.
1 group of embodiment, comparative example 1-4 groups), blank control group (not medication).
Medication：
Administration route：Diseased region dermal application.
Dosage rate and period：It is respectively administered once sooner or later daily, successive administration 5 days.
Four, test result
Living animal observation index：
General clinical observation：Including but not limited to death condition, the state of mind, behavioral activity, morbidity, breathing, secretion,
Excrement and diet and drinking-water situation etc..
Detailed clinical is observed：The including but not limited to state of mind, behavioral activity, skin, hair, eyes, ear, nose, abdomen
Portion, external genital organs, anus, four limbs, foot and breathing.
Weight：All animals after the receipt with weight is measured before grouping, and weight is measured before animal euthanasia.
Observation index：
Psoriasis model mice carries out tail skin scale number and measures, and optical microphotograph sem observation tail portion back side skin sample is cut
Piece cell counts the scale number (taking each group mouse weighted mean value) for having stratum granulosum in 100 scales.
Pruitus disease mouse model carries out itching number and the itching duration measures, and head is scratched with mouse fore paw,
Rear solid end scratches trunk, and mouth stings each position of whole body as itching indication, observes and records mouse itching number and itching in 30min and continues
Time (takes each group mouse assay average value).
Measure the record time：Before first administration and D6.
The front and back scale number containing stratum granulosum of 1 each test group animal of table administration
The front and back itching number of 2 each test group animal of table administration and itching duration
Test result：From table 1 it follows that compared with blank group, contain in each 100 scales of test medicine group mouse
The scale number of stratum granulosum has different degrees of reduction, and the psoriasis skin lesion degree of each group mouse is prompted to be mitigated, wherein
Embodiment group improvement degree is the most notable, illustrates that embodiment group drug is ideal to psoriasis treatment effect.Equally, in table
In 2, compared with blank group, also there are different degrees of reduction in each test medicine group mouse itching number and itching duration,
The skin itching symptom of prompt each group mouse is mitigated, and wherein embodiment group degree of alleviation is the most notable, illustrates embodiment
Group drug is ideal to the therapeutic effect of cutaneous pruritus.
To sum up, in addition to blank group, each test medicine group all has certain treatment skin disease effect, the treatment of embodiment group
Effect is the most prominent.In comparison, each comparative example group is due to having lacked certain components in composition of raw materials, to treating for skin disease
For effect far away from embodiment group, raw material type and proportioning composition to illustrate embodiment group drug are better than other comparative examples
Group, each component can generate its therapeutic effect important influence in this medicament composing prescription, just because of good between each raw material component
Good synergistic effect, has just established pharmacodynamic basis for treating skin disease.To sum up, why this drug can obtain ideal
Treatment skin disease effect, be each raw medicinal material effectively combine synergistic effect generate result.
Clinical test
This test objective is to observe and verify that drug of the present invention (drug in embodiment 1) is dermopathic to four types to be controlled
Therapeutic effect.
One, case selection and grouping
Each disease 60, is randomly divided into treatment group and control group, every group each 30.
Two groups of ages, gender, the course of disease, the not statistically significant (p of disease severity comparing difference>0.05).
Two, diagnosis basis and inclusion criteria
(1) age requirement 18-60 one full year of life；
(2) meet the clinical criteria of this disease；
(3) it tests in first 1 month and did not carried out other treatment；
(4) without other serious organ diseases；
(5) agree to participate in this experiment, and signed informed consent form.
Three, exclusion criteria
(1) age is below 18 one full year of life or 60 one full year of life above person；
(2) gestational period or women breast-feeding their children；
(3) there are allergies or allergic constitution person to this drug ingedient；
(4) it is associated with the severe primaries disease patient such as angiocarpy, liver, kidney or hemopoietic system；
(5) psychiatric patient.
Four, therapy
Treatment group：Drug (embodiment 1) ointment of the present invention smears disease sites skin, 2 times a day, 7 days 1 courses for the treatment of；
Control group：Positive drug is administered, 7 days 1 courses for the treatment of according to drug specification record method.
Five, observation index and curative effect determinate standard
Observation index：
Clinical indices：Day by day clinical symptoms, sign variation are observed during experiment, and monitor the hair of various adverse reactions closely
Raw time, performance, degree, processing and result.
Lab index：Check that blood, urine, feces are conventional before experiment and after being discontinued, Liver and kidney function.
Curative effect evaluation is classified：
It is divided into level Four according to clinical symptoms, the overall improvement degree of sign：
Recovery from illness：Clinical symptoms, sign restore normal；
It is effective：The state of an illness is clearly better, but not yet restores completely normal；
Improve：The state of an illness take a favorable turn, but not apparent enough；
In vain：The state of an illness is without improvement or adds severe one.
Recurrence rate is observed：To recovery from illness and effective case follow-up 3 months after medication, recurrence rate is recorded.
Six, treatment results
Treatment group and control group are treated 7 days and respectively after follow-up 3 months in four groups of experiments, clinical efficacy and recurrence rate statistics
As a result referring to the following table 3-6.
3 curing psoriasis group of table and control group curative effect comparision table
| Group | Number of cases | Recovery from illness | It is effective | Improve | In vain | Total effective rate | Recurrence rate |
| Treatment group | 30 | 6 | 16 | 7 | 1 | 96.7% | 4.5% |
| Fluocinonide ointment | 30 | 2 | 9 | 11 | 8 | 73.3% | 36.3% |
4 tinea of feet and hands treatment group of table and control group curative effect comparision table
| Group | Number of cases | Recovery from illness | It is effective | Improve | In vain | Total effective rate | Recurrence rate |
| Treatment group | 30 | 13 | 11 | 6 | 0 | 100.0% | 0% |
| Miconazole ointment | 30 | 5 | 14 | 6 | 5 | 83.3% | 21.0% |
5 impetigo treatment group of table and control group curative effect comparision table
| Group | Number of cases | Recovery from illness | It is effective | Improve | In vain | Total effective rate | Recurrence rate |
| Treatment group | 30 | 8 | 10 | 9 | 3 | 90.0% | 0% |
| Erythromycin ointment | 30 | 5 | 12 | 6 | 7 | 76.7% | 11.8% |
6 cutaneous pruritus treatment group of table and control group curative effect comparision table
| Group | Number of cases | Recovery from illness | It is effective | Improve | In vain | Total effective rate | Recurrence rate |
| Treatment group | 30 | 23 | 5 | 1 | 1 | 96.7% | 7.1% |
| Fluocinonide ointment | 30 | 8 | 5 | 10 | 7 | 76.7% | 38.5% |
As can be seen that using drug therapy psoriasis, tinea of feet and hands, impetigo and cutaneous pruritus of the present invention from table 3-6,
Its recovery from illness case load and total effective rate are far above positive control drug, to confirm drug of the present invention to above-mentioned four classes skin disease
With ideal therapeutic effect, and as its safety of pure natural medical and tolerance, there has also been significantly carry
It is high.In addition, it is further preferred that using its recurrence rate after the above-mentioned four classes skin disease of drug therapy of the present invention well below right
According to medicine, without recurrent cases in tinea of feet and hands and impetigo experiment, recurrence rate is also extremely low in psoriasis and cutaneous pruritus experiment, into one
Step demonstrates drug of the present invention has long-term therapeutic effect to skin disease.
The preferred embodiments of the disclosure and embodiment are explained in detail above, but the present invention is not limited to
The above-described embodiment and examples can also not depart from the present invention within the knowledge of those skilled in the art
Various changes can be made under the premise of design.
Claims (9)
1. a kind for the treatment of dermopathic drug, it is characterised in that it is made of the raw material of following weight parts：
Wild the root of straight ladybell 13-17；Frutus cnidii 13-17；Willow bark 13-17；
Sand ground willow buddings 28-32；Nepal knotweed herb grass 15-20；
The drug is made by following steps：
Wild the root of straight ladybell, frutus cnidii, willow bark, sand ground willow buddings and nepal knotweed herb herbal medicine material are mixed, water rinses, adds after dry, crushing
8-12 times is measured water, after impregnating 2 hours, is decocted 1-3 hours, and liquid filtration, filtrate is spare, repeats to decoct by the dregs of a decoction under the same conditions
It boils 1-3 times, continues to decoct until becoming sticky pasty masses up to this drug extract after merging filtrate.
2. dermopathic drug is treated as described in claim 1, wherein the parts by weight of each raw material are：
Wild the root of straight ladybell 13；Frutus cnidii 13；Willow bark 13；
Sand ground willow buddings 28；Nepal knotweed herb grass 15.
3. dermopathic drug is treated as described in claim 1, wherein the parts by weight of each raw material are：
Wild the root of straight ladybell 15；Frutus cnidii 15；Willow bark 15；
Sand ground willow buddings 30；Nepal knotweed herb grass 18.
4. dermopathic drug is treated as described in claim 1, wherein the parts by weight of each raw material are：
Wild the root of straight ladybell 17；Frutus cnidii 17；Willow bark 17；
Sand ground willow buddings 32；Nepal knotweed herb grass 20.
5. treating dermopathic drug as described in claim 1, it is characterised in that obtained drug extract is normal by this field
This drug paste, ointment or film is further made in the method for preparing paste, ointment or film of rule.
6. the dermopathic drug for the treatment of as described in any one in claim 1-5 is preparing the application in treating psoriasis drug.
7. the dermopathic drug for the treatment of as described in any one in claim 1-5 is preparing the application in treating tinea of feet and hands drug.
8. the dermopathic drug for the treatment of as described in any one in claim 1-5 is preparing the application in treating impetigo drug.
9. the dermopathic drug for the treatment of as described in any one in claim 1-5 is preparing answering in treating pruitus disease drug
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710076605.2A CN108420879A (en) | 2017-02-13 | 2017-02-13 | It is a kind of to treat dermopathic drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710076605.2A CN108420879A (en) | 2017-02-13 | 2017-02-13 | It is a kind of to treat dermopathic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108420879A true CN108420879A (en) | 2018-08-21 |
Family
ID=63155059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710076605.2A Pending CN108420879A (en) | 2017-02-13 | 2017-02-13 | It is a kind of to treat dermopathic drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108420879A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977916A (en) * | 2006-12-20 | 2007-06-13 | 北京润德康医药技术有限公司 | Chinese medicine composition for treating skin disease |
-
2017
- 2017-02-13 CN CN201710076605.2A patent/CN108420879A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977916A (en) * | 2006-12-20 | 2007-06-13 | 北京润德康医药技术有限公司 | Chinese medicine composition for treating skin disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463539B (en) | A kind of medicine for the treatment of eczema and its production and use | |
| CN1332686C (en) | Chinese medicine for treating tractures and preparation for making plaster thereof | |
| CN107095828A (en) | A kind of daily chemical product composition with skin barrier repair function and its production and use | |
| CN108686023A (en) | A kind of antipruritic moisturizing essential oil for treating geroderma itch | |
| CN109010776A (en) | A kind of external-use analgesic and preparation method thereof | |
| CN108420879A (en) | It is a kind of to treat dermopathic drug | |
| CN105287561A (en) | Medicinal composition for treating ulcerative colitis | |
| CN104587165A (en) | Preparation process of compound fenticonazole nitrate preparation | |
| CN104001059A (en) | Traditional Chinese medicine composition for treating acnes and preparation method and application thereof | |
| CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
| CN103705664B (en) | One treats psoriatic pharmaceutical composition and preparation method thereof | |
| Lofty et al. | Intralesional combined furosemide and digoxin in cutaneous warts treatment: A randomized controlled clinical trial | |
| CN105030920B (en) | A kind of Chinese medicine composition for treating canker sore and laryngopathy | |
| CN108403764A (en) | A kind of external preparation and preparation method for treating Facial Recurrent Dermatitis | |
| CN103285287B (en) | One treats psoriatic composition of medicine and preparation method thereof | |
| CN108114056A (en) | A kind of hair pharmaceutical composition and its preparation method and application | |
| CN106166287A (en) | A kind of Chinese medicine for treating skin pruritus | |
| CN106902175A (en) | A kind of Chinese medicine ointment for treating perianal eczema | |
| CN104623252B (en) | A kind of compound fenticonazole nitrate preparation and its application | |
| CN103919777A (en) | Medicinal composition for preventing and treating psoriasis and application thereof | |
| CN103933397A (en) | Medicine for treating eczema | |
| CN104547942B (en) | Rukang granules agent with slow releasing function and preparation method thereof | |
| CN108721451A (en) | A kind of foot refreshing powder of the prevention tinea pedis foot odour pin sweat containing Bee Pollen | |
| CN102727618B (en) | Application of Caulis et Folium Hedyotis Hedyotideae in preparation of drug or health product for promoting lead removing | |
| RAJU et al. | Analysis on a Series of Efficacy of Holistic Unani Treatment in Psoriasis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180821 |
|
| RJ01 | Rejection of invention patent application after publication |